Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

VYNE Therapeutics Inc. (MNLO)

Cash Flow Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19Dec-31-18Dec-31-17Dec-31-16Dec-31-15
   10-K10-K10-K10-K10-K10-K10-K10-K
Net income  -23.2-73.3255.695.274.2-29.1-14.1-4.6
Depreciation and amortization  0.10.10.30.40.30.00.0 
Asset impairment charges    54.3     
Stock-based compensation  4.38.118.14.95.31.50.60.1
Change in working capital   [+]-8.6-2.6-36.216.8-0.31.00.80.4
Other operating activities  -1.811.3-429.3-190.6-148.1-1.610.4 
Cash from operations  -29.2-56.4-137.1-73.4-68.7-28.2-2.3-4.2
   
Capital expenditures   [+]0.00.0-0.1-1.1-0.60.00.00.0
Sales of short-term investments, net   [+] 1.050.642.9-11.249.117.8 
Other cash from investing  15.7 38.6  -64.1-55.3 
Cash from investing  15.71.089.141.9-11.8-15.1-37.50.0
   
Issuance of common stock, net  1.576.061.613.791.5   
Option exercises   0.50.30.40.00.0 0.1
Financing costs       -0.9  
Other cash from financing  0.2-35.70.534.60.948.7 47.8
Cash from financing  1.739.861.848.092.449.50.047.7
   
Free cash flow  -29.2-56.4-137.2-74.5-69.2-28.2-2.3-4.2
        Per share (diluted)  ($9.17)($19.72)($4.23)($8.77)($10.71)($5.53)($0.46)($0.88)
   
Cash paid for interest   2.43.90.8    
Cash paid for income taxes      0.6   

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy